miércoles, 26 de marzo de 2025

FDA approves cabozantinib for adults and pediatric patients 12 years of age and older with pNET and epNET

https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-cabozantinib-adults-and-pediatric-patients-12-years-age-and-older-pnet-and-epnet?utm_medium=email&utm_source=govdelivery

No hay comentarios:

Publicar un comentario